Guidance for Healthcare Providers on Newest Guidelines for Over-the-Counter Drug Treatment of Mild Symptoms of COVID-19 - 29/05/24
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
On January 18, 2024, the US Centers for Disease Control and Prevention issued their most recent guidelines for over-the-counter drugs for coronavirus disease 2019 (COVID-19). Specifically, the organization stated that “Most people with COVID-19 have mild illness and can recover at home. You can treat symptoms with over-the-counter medicines, such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil), to help you feel better.”
In this review we consider the contributions of different types of evidence and conclude that healthcare providers should make individual clinical judgments for each of their patients in the selection of over-the-counter drugs to treat symptoms of COVID-19. This judgment should be based on the entire benefit to risk profile of the patient. It is our belief that the individual healthcare provider knows far more about each of his or her patients than anyone, including expert members of guideline committees. Their astute and judicious individual clinical decision-making for each individual patient based on all these considerations has the potential to do far more good than harm.
Le texte complet de cet article est disponible en PDF.Keywords : Cardiovascular, COVID-19, Gastrointestinal, Guidance, Guidelines, Mild Symptoms, Over-the-Counter Drugs, Treatment
| Funding: None. |
|
| Conflict of Interest: DLD reports that he is partially supported by a National Institutes of Health grant to the University of Wisconsin for the Clinical Translational Science Award for statistical consultation and collaboration and administrative leadership, serves or has recently served as an independent biostatistician in an advisory role to investigators and sponsors often as a member of independent data and safety monitoring boards for Actelion, Amgen, Astellas, AstraZeneca, Biotronik, Boehringer-Ingelheim, CVRx, Genentech, GlaxoSmithKline, Novartis, Merck, Pfizer, Roche, Sanofi Aventis, Takeda, Millennium, the Duke Clinical Research Institute, the Population Health Research Institute of McMaster University, and Harvard Partners; receives royalties from publishers of the 3 textbooks that he has coauthored and edited; has tax-sheltered retirement accounts in mutual funds with Fidelity and Morgan Stanley; and has a small account of stock with Intel. CHH reports that he serves as an independent scientist in an advisory role to investigators and sponsors as chair of data monitoring committees for Amgen and UBC; to the US Food and Drug Administration and UpToDate; receives royalties for authorship or editorship of 3 textbooks; and has an investment management relationship with the West-Bacon Group within Truist Investment Services, which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company. All other authors report no conflicts of interest. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 137 - N° 6
P. 490-493 - juin 2024 Retour au numéro
Article précédent
- Complications of Radial vs Femoral Access for Coronary Angiography and Intervention: What Do the Data Tell Us?
- Chayakrit Krittanawong, Lakshmi Uppalapati, Hafeez Ul Hassan Virk, Yusuf Kamran Qadeer, Umer Irshad, Zhen Wang, Samin Sharma, Hani Jneid
- Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2023
- Majken T. Wingo, Carl A. Andersen, Shari L. Bornstein, Jill M. Huber, Jason H. Szostek, Mark L. Wieland
Bienvenue sur EM-consulte, la référence des professionnels de santé.